User profiles for Ajay Major
 | Ajay Major, MD, MBAUniversity of Colorado School of Medicine Verified email at cuanschutz.edu Cited by 697 |
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an …
A Major, J Collins, C Craney, AK Heitman… - Leukemia & …, 2021 - Taylor & Francis
Chimeric antigen receptor T-cell (CAR-T) therapy has significantly improved survival for adult
patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL). However, there are …
patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL). However, there are …
Using big data in pediatric oncology: Current applications and future directions
Pediatric cancer is a rare disease with a low annual incidence, which presents a significant
challenge in being able to collect enough data to fuel clinical discoveries. Big data registry …
challenge in being able to collect enough data to fuel clinical discoveries. Big data registry …
PD-1 blockade in mediastinal gray-zone lymphoma
PD-1 Blockade in Mediastinal Gray-Zone Lymphoma | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
Prophylaxis is commonly used to prevent central nervous sy stem (CNS) relapse in diffuse
large B-cell lymphoma (DLBCL), with no clear standard of care. We retrospectively evaluated …
large B-cell lymphoma (DLBCL), with no clear standard of care. We retrospectively evaluated …
[HTML][HTML] To bully and be bullied: harassment and mistreatment in medical education
A Major - AMA Journal of Ethics, 2014 - journalofethics.ama-assn.org
In 1990, pediatrician Henry K. Silver first documented the rampant problem of medical student
mistreatment in a study reported in JAMA, which found that 46.4 percent of students at one …
mistreatment in a study reported in JAMA, which found that 46.4 percent of students at one …
[HTML][HTML] DA-R-EPOCH vs R-CHOP in DLBCL: how do we choose?
A Major, SM Smith - Clinical advances in hematology & oncology …, 2021 - ncbi.nlm.nih.gov
The emerging molecular and prognostic characterization of diffuse large B-cell lymphoma (DLBCL)
has challenged the rituximab, cyclophosphamide, doxorubicin, vincristine, and …
has challenged the rituximab, cyclophosphamide, doxorubicin, vincristine, and …
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple …
…, JA Zonder, K Griffith, A Stefka, A Major… - The Lancet …, 2023 - thelancet.com
Background Lenalidomide is a cornerstone of maintenance therapy in patients with newly
diagnosed multiple myeloma after autologous stem-cell transplantation. We aimed to compare …
diagnosed multiple myeloma after autologous stem-cell transplantation. We aimed to compare …
Persistence of Ad26. COV2. S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies
Rare cases of COVID‐19 vaccinated individuals develop anti‐platelet factor 4 (PF4) antibodies
that cause thrombocytopenia and thrombotic complications, a syndrome referred to as …
that cause thrombocytopenia and thrombotic complications, a syndrome referred to as …
[HTML][HTML] Documenting social media engagement as scholarship: a new model for assessing academic accomplishment for the health professions
Background The traditional model of promotion and tenure in the health professions relies
heavily on formal scholarship through teaching, research, and service. Institutions consider …
heavily on formal scholarship through teaching, research, and service. Institutions consider …
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
Checkpoint inhibitor (CPI) therapy with anti–PD-1 antibodies has been associated with
mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after …
mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after …
